SUZANNE SWAIN: Open Payments
NPI 1790245678 · SCOTTSDALE, AZ. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$313 in 14 payments from 9 companies in 2025. Trend: 2023 $204 · 2024 $366 · 2025 $313
Food & beverage: $313
| Company | Payments | Amount |
|---|---|---|
| Otsuka America Pharmaceutical, Inc. | 3 | $80 |
| Neurocrine BioSciences, Inc. | 2 | $51 |
| Alkermes, Inc. | 2 | $48 |
| ABBVIE INC. | 2 | $30 |
| Indivior Inc. | 1 | $29 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 1 | $23 |
| Vanda Pharmaceuticals Inc. | 1 | $20 |
| E.R. Squibb & Sons, L.L.C. | 1 | $17 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $17 |
Products named: REXULTI, INGREZZA, ARISTADA, VRAYLAR, SUBLOCADE, CAPLYTA, HETLIOZ, COBENFY.
Industry payments across AZ — which companies pay providers there.
